Efficacy and safety of a prothrombin complex concentrate (Octaplex®) for rapid reversal of oral anticoagulation

Thrombosis Research

Volumn 113, Issue 6, 2004, Pages 371-378

  Lubetsky, Aaron ^a   Hoffman, Ron ^b   Zimlichman, Reuven ^d   Eldor, Amiram ^c   Zvi, Joseph ^d   Kostenko, Viktor ^e   Brenner, Benjamin ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c Ichilov Medical Center   (Israel)

^d WOLFSON MEDICAL CENTER   (Israel)

^e Inst Emergency Cure II Dzhanelize   (Russian Federation)

Author keywords

Oral anticoagulation; Prothrombin complex concentrates

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; OCTAPLEX; PROTHROMBIN COMPLEX;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NANOFILTRATION; PRIORITY JOURNAL; THROMBOGENICITY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; COAGULANTS; FEMALE; HEMORRHAGE; HUMANS; ISRAEL; MALE; MIDDLE AGED; RUSSIA; TREATMENT OUTCOME;

EID: 3042600900     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.04.004     Document Type: Article

References (19)

1. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 348:1996;423-428
2. van der Meer F.J.M., Rosendaal F.R., Vandenbroucke J.P., Briet E. Bleeding complications in oral anticoagulant therapy. Arch. Intern. Med. 153:1993;1557-1562
3. Cannegieter S., Rosendaal F.R., Wintzen A., van der Meer F.J.M., Vandenbroucke J.P., Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med. 333:1995;11-17
4. Makris M., Watson H.G. The management of coumarin-induced over-anticoagulation Annotation. Br. J. Haematol. 114:2001;271-280
5. Baglin T. Management of warfarin (coumarin) overdose. Blood Reviews. 12:1998;91-98
6. Makris M., Greaves M., Phillips W.S., Kitchen S., Rosendaal F.R. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb. Haemost. 77:1997;477-480
7. Seitz R., Dodt J. Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb. Res. 95:1999;s19-s23
8. Kohler M., Hellstern P., Lechler E., Uberfuhr P., Muller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb. Haemost. 80:1998;399-402
9. Josic D.J., Hoffer L., Buchacher A., Schwinn H., Frenzel W., Biesert L., et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb. Res. 100:2000;433-441
10. Taberner D.A., Thomson J.M., Poller L. Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. BMJ. 2:1976;83-85
11. Fredriksson K., Norrving B., Stromblad L.G. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 23:1992;972-977
12. Boulis N.M., Bobek M.P., Schmaier A., Hoff J.T. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 45:1999;1113-1119
13. Cartmill M., Dolan G., Byrne J.L., Byrne P.O. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br. J. Neurosurg. 14(5):2000;458-461
14. Evans G., Luddington R., Baglin T. Beriplex T/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br. J. Haematol. 2001;998-1001
15. Preston F.E., Laidlaw S.T., Sampson B., Kitchen S. Rapid reversal of oral anticoagulation by a prothrombin complex concentrate (beriplex): efficacy and safety in 42 patients. Br. J. Haematol. 116:2002;619-624
16. Jordan J., Tiangco B., Kiss J., Koch W. Human parvovirus B-19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 75:1998;97-102
17. Heegaard E.D., Brown K.E. Human parvovirus B-19. Clin. Microbiol. Rev. 15:2002;485-505
18. Williams M.D., Cohen B.J., Beddall A.C., Pasi K.J., Mortimer P.P., Hill F.G. Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang. 58(3):1990;177-181
19. Santagostino E., Mannucci P.M., Gringeri A., Azzi A., Morfini M., Musso R., et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees after lyophilization. Transfusion. 37(5):1997;517-522